medcelerator · clinician one-pager

First FDA-Approved Gene Therapy Sheets for RDEB Wounds

Zevaskyn (prademagene zamikeracel) — gene-modified cellular sheets surgically applied to treat wounds in recessive dystrophic epidermolysis bullosa

FDA Approved · United States · September 18, 2026

Condition: Recessive Dystrophic Epidermolysis Bullosa

Who this is for

This is for people living with recessive dystrophic epidermolysis bullosa — and the caregivers who help them — who have chronic open wounds and may be candidates for labelled US Zevaskyn autologous gene-modified cell sheets at a Qualified Treatment Center after punch biopsies, ~25-day manufacturing, and a single surgical application session. It explains the first FDA-approved RDEB cell-sheet gene therapy, the VIITAL Month-6 healing and pain results, hypersensitivity and lifelong malignancy-watchpoint honesty, Abeona Assist navigation, and why authorised is not funded — without treating completed research as walk-in enrolment, treating an incomplete centre list as permanent, or importing a US sheet lot. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

Ways to access this treatment

United States · Prescription
US prescription (FDA-labelled)
https://www.fda.gov/vaccines-blood-biologics/zevaskyn

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/zevaskyn-prademagene-zamikeracel